CDH17 and neoplasm: The results indicated that the high levels of CDH17 immunohistochemical expression in tumor emboli (p = 0.028), with a hazard rate (HR) of 2.003 (95% CI: 1.077–3.723), may function as an independent prognostic factor (Table 3).